An open-label, randomized study of 3 manufacturing consistency lots of (VAQTA) in healthy children and adolescents 2–17 years of age
Latest Information Update: 28 Apr 2021
Price :
$35 *
At a glance
- Drugs Hepatitis A vaccine inactivated (Primary)
- Indications Hepatitis A
- Focus Pharmacodynamics
- 28 Apr 2021 New trial record
- 15 Apr 2021 Results summarizing the statistical models developed to evaluate the long-term persistence and duration of detectable hepatitis A antibody after receipt of HAVi in healthy children and adolescents (V251-023 and V251-035) and in healthy adults (V251-034), published in the Vaccine.